Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation by Kormelink, Tom Groot et al.
Oncotarget3159www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 10
Immunoglobulin free light chains are biomarkers of poor 
prognosis in basal-like breast cancer and are potential targets 
in tumor-associated inflammation
Tom Groot Kormelink1,*, Desmond G. Powe2,*, Sylvia A. Kuijpers3, Abulikemu 
Abudukelimu3, Marcel H.A.M. Fens3, Ebel H.E. Pieters3, Willemiek W. Kassing-van 
der Ven3, Hany O. Habashy4, Ian O. Ellis5, Bart R. Blokhuis1, Marco Thio1, Wim E. 
Hennink3, Gert Storm3, Frank A. Redegeld1,7, and Raymond M. Schiffelers6,7
1 Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, 
The Netherlands
2 Department of Cellular Pathology, Queen’s Medical Centre, Nottingham University Hospitals Trust, Nottingham, UK & The 
John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK
3 Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, 
The Netherlands
4 Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
5 Department of Pathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University 
Hospitals NHS Trust, Nottingham, UK
6 Laboratory of Clinical Chemistry & Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
7 These authors share equal senior authorship
* These authors contributed equally
Correspondence to: Frank Redegeld, email: f.a.m.redegeld@uu.nl
Correspondence to: Raymond Schiffelers, email: r.schiffelers@umcutrecht.nl
Keywords: immunoglobulin free light chain, mast cell, biomarker, inflammation, tumor progression
Received: January 23, 2014 Accepted: March 24, 2014 Published: March 26, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Inflammation is an important component of various cancers and its inflammatory 
cells and mediators have been shown to have prognostic potential. Tumor-infiltrating 
mast cells can promote tumor growth and angiogenesis, but the mechanism of mast 
cell activation is unclear. In earlier studies, we demonstrated that immunoglobulin 
free light chains (FLC) can trigger mast cells in an antigen-specific manner. Increased 
expression of FLC was observed within stroma of various human cancers including 
those of breast, colon, lung, pancreas, kidney and skin, and FLC expression co-
localized with areas of mast cell infiltration. In a large cohort of breast cancer patients, 
FLC expression was shown associated with basal-like cancers with an aggressive 
phenotype. Moreover, lambda FLC was found expressed in areas of inflammatory 
infiltration and its expression was significantly associated with poor clinical outcome. 
Functional importance of FLCs was shown in a murine B16F10 melanoma model, 
where inhibition of FLC-mediated mast cell activation strongly reduced tumor growth. 
Collectively, this study identifies FLCs as a ligand in the pro-tumorigenic activation of 
mast cells. Blocking this pathway may open new avenues for the inhibition of tumor 
growth, while immunohistochemical staining of FLC may be helpful in the diagnosis 
and prognosis of cancer.
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INTRODUCTION
Inflammation is considered a critical component 
of tumor progression in some cancer types [1]. The 
crosstalk between inflammatory cells and tumor 
cells provides a tumor microenvironment that favors 
proliferation, invasion, migration and metastasis. The 
mast cell is an important organizer of the tumor associated 
microenvironment and inflammatory reactions contained 
within it [2, 3]. Through the release of cytokines and 
proteases, mast cells promote angiogenesis and tissue 
degradation and furthermore, they function as important 
intermediates in regulatory T cell-induced tolerance [4, 
5]. Mast cells are seen infiltrating the periphery of many 
human tumors such as breast carcinoma, malignant 
melanoma, colorectal adenocarcinoma, and oral squamous 
cell carcinoma. Some studies suggest that mast cells may 
inhibit tumor growth and improve prognosis, evidenced by 
a lack of correlation between mast cells with angiogenesis 
and clinical outcome [2, 3, 6-9]. However, other studies 
indicate that the number of mast cells correlates with an 
increase in intra-tumoral microvessel density, enhanced 
tumor growth and invasion, and poor clinical outcome 
[6, 10-12]. In addition, mast cells can recruit other 
inflammatory cells including macrophages that are 
implicated in promoting cancer invasion and metastasis 
[13, 14]. These findings are supported by recent studies 
in various experimental tumor models that demonstrate 
an essential role for mast cells in tumor expansion [10, 
15-17].
Mast cells are activated by the crosslinking of IgE 
and IgG antibodies on specific receptors resulting in 
the release of vasoactive and inflammatory mediators. 
Activation can also be induced by other signals, such as 
complement factors, cytokines, inflammatory mediators, 
toll-like receptor ligands, and by T-cells [18]. Importantly, 
we have previously shown that immunoglobulin free 
light chains (FLCs) can activate mast cells in an antigen-
specific manner [19, 20], and along with IgE and IgG, 
FLCs are an important component of the humoral immune 
response to antigen exposure.
Recent studies have shown that non-clonal elevation 
of FLC is a significant predictor of worse overall survival 
in patients without plasma cell disorders. Interestingly, 
neoplastic conditions were amongst the most frequent 
causes of mortality in patients with high polyclonal FLC 
[21, 22].
We hypothesized that FLC may be involved in the 
activation of tumor-infiltrating mast cells and thereby 
influence tumor growth and progression. In this study, we 
investigated the presence and functional role of FLC in 
tumor-associated inflammation. In addition, we analyzed 
the expression of FLC in human cancer of the breast, 
colon, lung, pancreas, kidney and skin, and we assessed 
the clinical significance in a large cohort of breast cancer 
patients with long term clinical follow-up [23].
RESULTS
Localization of FLC expression in different 
human tumor types
The cellular localization of kappa and lambda FLC 
protein expression was investigated in tissue microarrays 
Figure 1: Immunoglobulin free 
light chains are expressed in breast, 
pancreas, lung, colon, skin and kidney 
cancer biopsies. (A-C) The FLC staining 
pattern was discriminated by three categories: 
+, isolated FLC-positive cells (A); ++, clusters 
of ≥ 10 FLC-positive cells (B); or +++, 
clusters of FLC-positive cells encompassing 
more than 10 % of the tissue core (C) (original 
magnification, x100). (D) Percentage of 
FLC-positive malignant, cancer-adjacent or 
normal tissue biopsies (diameter 1.5 mm) 
from breast, pancreas, lung, colon, skin and 
kidney. The numbers next to each bar indicate 
the number of positive samples divided by the 
total number of individual patient biopsies 
examined. The color intensity of the bar 
corresponds to the degree of FLC staining. 
Biopsies were evaluated by two researchers 
who were blinded to the tissue status. (E-F) 
Expression of FLC (E) and infiltration of mast 
cells (tryptase staining) (F) were found in same 
areas in tumor tissue (original magnification, 
x200).
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(TMA) comprising human cancer specimens derived from 
breast, pancreas, lung, colon, skin, and kidney. Staining 
was evaluated in 642 samples of tumor tissue, adjacent 
tissue and normal control tissue (Supplementary Table 
1) using a 3-point scoring method: +, isolated FLC-
positive cells; ++, clusters of ≥ 10 FLC-positive cells; or 
+++, clusters of FLC-positive cells encompassing more 
than 10% of the tissue core (Figure 1A-C). FLC staining 
was noted in 201 out of 474 cancer tissue cores (42%) 
(Figure 1D and Supplementary Table 1). Approximately 
30% of the breast and pancreatic cancer samples showed 
FLC positive cells, whereas > 50% of lung, kidney, 
skin and colon cancer samples were FLC-positive. FLC 
staining was virtually absent in healthy tissue control 
samples, only 2/87 control samples showed any positivity. 
Immunohistochemistry was used to assess the distribution 
of mast cells and they were found in essentially all tumor 
samples (143 out of 150 cases (95%)). Frequently, FLCs 
(Figure 1E) and mast cells (Figure 1F) were present in 
the same regions supporting co-localization of FLC to this 
cell type. 
Association of FLC expression and breast cancer
To investigate the clinical significance of FLC 
protein expression in human cancer, kappa and lambda 
FLC expression was analyzed using a breast cancer tissue 
microarray comprising approximately 700 female patients 
(aged <75) derived from the Nottingham Tenovus Primary 
Breast Carcinoma Series (1986-1998) [23]. This well 
characterized resource contains information on patients’ 
clinical and pathological data and comprises two tissue 
cores per patient, representing the tumor periphery and 
centre. A striking differential expression of the FLC 
isotypes was found. Protein expression of kappa FLC was 
predominantly localized in the cytoplasm of malignant 
breast cells and less frequently in inflammatory cells 
of the adjacent stroma. In contrast, strong lambda FLC 
expression was seen in stromal inflammatory cells but was 
only rarely seen in the cytoplasm of cancer cells (Figure 
2).
FLC-positive patients showed no significant 
difference in age or tumor recurrence compared to FLC 
negative patients. Lambda but not kappa FLC expression 
was significantly increased in premenopausal patients 
(p=0.014). Kappa and lambda FLC protein expression 
showed significant positive correlations with increased 
tumor size, tumor grade and clinical stage (node 
involvement), poor NPI+ (Nottingham Prognostic Index), 
and vascular invasion (kappa p<0.007; lambda p<0.002). 
FLC positivity was under-represented in the low nuclear 
grade family of tumor types [30], including tubular 
cancers, but was increased in ductal and medullary type 
cancers (p<0.001). Kappa and lambda FLC expression 
showed significant negative correlations with tumor-
relevant markers usually associated with favorable 
Figure 2: Lambda FLCs are found co-localized to regions of inflammation in breast tumors and their presence predicts 
worse breast cancer prognosis.(A) Using immunohistochemistry Lambda FLC was found localized to inflammatory cells located 
close to medullary breast cancer cells (B) Kappa FLC protein expression (arrow) was detected in the cytoplasm of ductal breast cancer cells 
(original magnification, A and B, x100), (C) Kaplan-Meier plots showing patients with lambda FLC positive cells had reduced breast cancer 
specific survival, reduced time in forming metastases, reduced disease-free interval and reduced time to tumor recurrence.
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clinical outcome including the hormonal receptor markers 
for estrogen and progesterone and the apoptotic marker 
Bcl2 (p<0.001). Instead, significant positive associations 
were seen with markers of aggressive tumor phenotype 
such as basal-like markers including cytokeratin (CK) 
5/6 and EGFR (p<0.0001), and the proliferation marker 
MIB1 (p<0.002), mutated p53 and BRCA1 (p<0.0001), 
and HER2 (kappa: p=0.004).
Multivariate Cox regression (hazards ratio: HR) 
was performed to test the independence of kappa and 
lambda FLC protein expression against established 
prognostic variables including tumor size, stage, grade, 
vascular invasion, chemotherapy and endocrine therapy, 
for predicting breast cancer specific survival (BCSS). 
FLC was not found to be an independent prognosticator of 
survival. Kaplan-Meier modeling for clinical outcome in 
the full patient cohort showed no significant associations 
between kappa FLC protein expression and BCSS (chi-
square=2.448, p=2.448), disease-free interval (DFI) (chi-
square=2.222, p=0.136), shortened time for metastases 
formation (DM) (chi-square=2.234, p=0.135), or tumor 
recurrence (chi-square =1.307, p=0.253). However, 
lambda FLC expression showed a highly significant 
correlation with decreased BCSS (chi-square=18.0, 
p<0.0001), DFI (chi-square=15.2, p<0.0001), DM (chi-
square=13.6, p=0.0002), and tumor recurrence (chi-
square=17.6, p<0.0001) (Figure 2C).
The functional role of FLC in supporting tumor 
growth in a mouse melanoma model
In earlier work we have shown that mast cells can 
be activated by FLCs (14,15). The functional importance 
of the association between FLCs and mast cells in tumor 
development and growth was further investigated in 
an in vivo melanoma mouse model, in which tumor-
associated inflammation is an important driver for tumor 
growth [31]. Using western blotting, we demonstrated the 
presence of FLC proteins in subcutaneously implanted 
B16F10 melanoma in C57Bl/6J mice (Figure 3A). The 
tumor tissue contained monomeric (25 kDa) and dimeric 
(50 kDa) forms of FLC. Isolated B16F10 melanoma cells 
Figure 3: FLCs are responsible for mast cell activation supporting tumor growth of B16F10 melanoma.(A) Immunoblot 
analysis of FLC monomers (25 kD) and dimers (50 kD) in homogenized B16F10 tumor tissue. Each lane represents a tumor isolated from 
an individual animal. (B-C) Toluidine blue staining of mast cells in B16F10 melanoma tissue showing peri-tumoral and intra-tumoral mast 
cells. All of the melanomas were isolated from B16F10 inoculated wild type mice. (D-F) Mast cell deficiency and the FLC antagonist 
F991 attenuate B16F10 melanoma growth. (D) Tumor growth in PBS-treated wild type C57Bl/6 (closed circles) and mast cell-deficient 
WBB6F1/J-KitW/KitW-v (open circles) mice. (E) Tumor growth in wild type C57Bl/6 (left) and mast cell-deficient WBB6F1/J-KitW/KitW-v 
(right) mice treated weekly with 20 µg F991 (open circles) or PBS (closed circles) intra-tumorally. Data are the mean ± SEM, n = 10 
animals/experimental group, * indicates p < 0.05 by comparing total areas under the curve (D and E). (F) Time-to-reach-humane-endpoint 
in wild type C57Bl/6 (left) and mast cell-deficient WBB6F1/J-KitW/KitW-v (right) mice treated weekly with 20 µg F991 (open circles) or 
PBS (closed circles) intra-tumorally. n = 10 animals/experimental group, * indicates p < 0.05. Effects of F991 were tested in 4 independent 
replicate experiments.
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did not produce FLCs in vitro (data not shown). Mast cell 
infiltration, a prominent feature of B16 melanoma models 
[9, 32, 33], was also observed, especially at the tumor 
periphery using toluidine blue staining (Figure 3B-C).
The possible functional role of FLCs and mast 
cells in tumor growth in the B16F10 melanoma model 
was investigated both in wild type C57Bl/6J mice that 
possess normal numbers of mast cells and mast cell-
deficient WBB6F1/J-KitW/KitW-v mice. After subcutaneous 
melanoma cell inoculation, the average time for the 
tumors to become palpable was 7.7 ± 0.5 days in 
C57Bl/6J mice (mean ± SD, n = 20) and 7.5 ± 1.4 days 
for WBB6F1/J-KitW/KitW-v mice (mean ± SD, n = 20). 
However, subsequent tumor growth was greatly reduced 
in WBB6F1/J-KitW/KitW-v mice (p=0.03 comparing areas 
under the tumor growth curve), confirming a critical 
role for mast cells in B16F10 melanoma tumor growth 
(Figure 3D) [9, 32, 33]. The role of FLC-induced mast 
cell activation in supporting tumor growth was further 
investigated by using a specific peptide FLC antagonist 
(F991) [19]. When tumors were palpable, the animals 
were treated intra-tumorally with weekly doses of 20 
μg F991 or with vehicle (PBS) alone. In the wild type 
C57Bl/6J mice, F991 greatly reduced tumor growth when 
treated with F991. The vehicle-treated wild type animals 
were culled at day 9 after the first treatment because they 
had reached the humane endpoint (tumor volume≥1500 
mm3). F991-treated wild type animals showed an average 
61% lower tumor volume (p=0.03) and a 49% reduction 
in growth rate (p=0.02; total area under the tumor growth 
curve) compared to non-F991 treated control animals 
(Figure 3E). Four replicate experiments were performed 
and the volumes of F991-treated tumors were between 52 
and 76% smaller than those of controls. The median time-
to-reach-the-humane-endpoint in F991-treated wild type 
mice was also increased to 13 days compared to 10 days 
in vehicle-treated wild type controls (p=0.03, log-rank 
(Mantel-Cox) test) (Figure 3F). As expected, F991 did 
not affect tumor growth in mast cell-deficient WBB6F1/
J-KitW/KitW-v (Figure 3E), nor did it affect the median 
survival time in mast cell-deficient animals (Figure 3F). 
DISCUSSION
In this study, we provide evidence for the 
involvement of FLCs in cancer pathology. FLC protein 
expression was detected in tumor-associated tissue from 
human breast, pancreas, lung, colon, skin and kidney, 
while FLC staining was virtually absent in comparative 
healthy tissue. The production of FLC was co-localized 
with mast cell infiltrates in tumor tissue leading to the 
proposal that FLC can activate mast cells occurring in 
peri-tumoral inflammation. The clinical significance of 
FLC isotype expression was studied in a well-defined large 
cohort of female breast cancer patients with long-term 
follow-up. We showed that FLC expression is associated 
with an aggressive tumor trait, particularly those with a 
triple-negative (estrogen receptor, progesterone receptor 
and HER2 negative) basal-like phenotype. In addition, 
FLC expression correlated with several molecular 
markers of poor disease prognosis evidenced by increased 
cell proliferation, reduced apoptosis and p53 mutation. 
Recently, triple-negative and aggressive breast cancer 
signatures have been associated with specific inflammatory 
mediators [34, 35]. Strikingly, whereas kappa and lambda 
FLC both indicated aggressive tumor features, only 
lambda FLC showed a significant reduction in breast 
cancer-specific survival, disease free interval, time to 
metastasis, and time for tumor recurrence. This suggests 
that these FLC positive cells, possibly mast cells because 
of its co-localization with regions of mast cell infiltration, 
are markers of high risk patients needing more intensive 
clinical management. The biological significance of kappa 
FLC localization in neoplastic epithelium is not apparent 
and requires further study. Recently, it was shown that 
IgG can be produced by breast cancer cells [36], which 
could possibly attribute to the presence of kappa FLC in 
malignant breast cancer cells observed here. Our study 
indicates that micro-localization of the expression of FLC 
in tumor tissue near peri-tumoral inflammatory cells is 
of importance for aggravated tumor pathology and poor 
clinical outcome. To our knowledge this is the first study 
to show the different localized expression of kappa and 
lambda FLC isoforms in tumor tissue. Further studies are 
needed to understand its relation to inflammation-driven 
tumor development and growth.
A possible functional importance of FLC to tumor 
growth was further explored in a murine model of human 
malignant melanoma using B16F10 cells. This tumor 
model responds to anti-inflammatory therapy [31] and 
is dependent on mast cells [9, 32, 33]. In this study, it 
was shown that FLC expression occurs associated with 
these murine tumors as well. Inhibition of FLCs by the 
antagonist F991, a peptide which binds to FLC [19, 
37], greatly reduced melanoma tumor growth. F991 
specifically prevents mast cell activation by FLCs, but 
has no effect on activation by IgG or IgE [19] nor does 
F991 directly activate mast cells to induce degranulation 
(data not shown). Current data suggest that FLC may 
activate tumor-associated mast cells to produce mediators 
that enhance tumor growth, or that activated mast cells 
instruct the production of autocrine growth factors by the 
tumor. Furthermore, the reduced tumor growth in mast 
cell deficient-mice and the unresponsiveness of B16F10 
melanoma in these mice to F991 treatment further 
underscores a critical role of FLC-mediated mast cell 
activation on inflammation in tumor progression. These 
observations suggest that using a FLC receptor antagonist 
such as F991 could offer a novel therapeutic approach for 
slowing cancer growth and improving specific survival 
time. 
As B16F10 melanoma cells do not produce FLCs 
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in vitro, indicating that systemic FLCs infiltrate into the 
tumor, or that local B cells or plasma cells are a source 
of FLCs. B cell infiltration and antibody production have 
been shown to precede premalignant transformation and to 
enhance tumor proliferation [27, 38]. 
A number of different biological mechanisms have 
been proposed to explain how mast cells affect tumor 
growth, predominantly in experimental tumor models [2, 
3, 6-8, 17]. The effect of mast cell activation at the tumor 
site appears to depend on tumor localization (intra- or peri-
tumoral) [39], stimulating factor [9], and degree of mast 
cell activation [40, 41]. Timing is also important. Mast 
cells entering the tumor microenvironment at an early 
stage appear to promote angiogenesis which is crucial 
for tumor growth [15, 42-44]. In addition, mast cells can 
induce an immunosuppressive tumor microenvironment 
[17] by directly enhancing regulatory T cell (Treg) 
function via mast cell-T cell contact [44], IL-10 [46], 
tryptophan metabolism [47], amphiregulin production 
[48], or adenosine [44], or indirectly by inducing 
tolerogenic dendritic cells [5]. Furthermore, mast cells 
serve in attracting other inflammatory cells including 
macrophages that are implicated in initiating cell signaling 
events involved in colonic tumor invasion [13] and breast 
cancer metastasis [14].
In our previous studies, FLC-mediated mast cell 
activation has been associated with the induction of 
several inflammatory disorders [19, 49, 50]. Present 
data suggest that FLC could contribute to tumor growth. 
It remains to be determined if FLC-induced mast cell 
activation is mediated via induction of e.g. immune 
tolerance, stimulation of angiogenesis and/or release 
of other pro-tumorigenic factors. Because FLC are able 
to bind antigen with reasonably high affinities [20] and 
antigen-specific FLC can be detected in human patients 
(manuscript in preparation), it will be interesting to 
determine the antigen-specificity of the FLC present 
in tumor tissues in future research. Alternatively, FLC-
binding to mast cells without subsequent antigen binding 
might result in selective mediator release as was shown 
for IgE, which enhances VEGF release and thereby 
contributes to melanoma tumor growth [51].
In conclusion, our study suggests that FLC activated 
mast cells are associated with increased tumor growth in 
a preclinical tumor model. Increased FLC expression in 
stroma of breast cancer tissue showed to be associated 
with reduced specific survival. This paradigm appears 
to extend to other tumor types too. Blocking FLC with 
the antagonist F991 demonstrates a novel strategy for 
therapeutically modifying mast cell-mediated cancer 
growth.
MATERIALS AND METHODS
Detection of FLC-positive cells and mast cells 
in tissue arrays of different human tumor types tissue 
array slides from US Biomax (Rockville, MD) were 
stained using the Envision G2 System/AP (rabbit/
mouse; DakoCytomation) according to manufacturer’s 
instructions. Separate sections were stained for kappa 
and lambda FLCs simultaneously [24] (Fκ-C8 and Fλ-G9 
purchased from Dr. A. Solomon, Tennessee; both 1 μg/
mL) and mast cell tryptase (clone AA1, DakoCytomation; 
0.4 μg/mL). The specific recognition of κ and λ FLCs by 
mAbs Fκ-C8 and Fλ-G9 in immunohistochemistry has 
been demonstrated earlier by Davern et al [24].
Primary antibodies were diluted in Tris-buffered 
saline containing 0.1% Triton X-100 and 1% bovine serum 
albumin. For tryptase staining, tissue deparaffinization was 
followed by heat-induced epitope retrieval using citrate 
buffer (10 mM citric acid containing 0.05 % Tween-20, 
pH 6). Slides were counterstained with hematoxylin. 
Sections were viewed using an Eclipse TE2000-U inverted 
microscope with 4x and 40x objectives (Nikon). Images 
were analyzed using NIS elements BR 2.3 software 
(Nikon). FLC staining was differentiated as follows: 
– (absence of staining), + (isolated cells with positive 
staining for FLC), ++ (clusters of ≥ 10 cells with positive 
staining for FLC), or +++ (clusters of cells encompassing 
> 10 % of the tissue core with positive staining for FLC). 
Staining was scored by two researchers who had no 
knowledge of biopsy status.
Patient studies
Patient selection for detailed analysis of FLC 
expression in breast cancer
Tissue microarray (TMA) slides from the 
Nottingham Breast Cancer group were used in this study 
comprising approximately 700 patients from women 
aged 70 or less derived from the Nottingham Tenovus 
Primary Breast Carcinoma Series (1986 and 1999). This 
well characterized resource contains information on 
patients’ clinical and pathological data including histologic 
tumor type, primary tumor size, lymph node status, 
histologic grade, and data on other breast cancer relevant 
biomarkers [23]. Patients within the good prognostic 
group (Nottingham Prognostic Index (NPI) ≤3.4) did not 
receive adjuvant therapy (AT) [25]. Hormonal therapy 
(HT) was prescribed to patients with ER-α+ tumors 
and NPI scores of >3.4 (moderate and poor prognostic 
groups). Pre-menopausal patients within the moderate 
and poor prognostic groups were candidates for CMF 
(Cyclophosphamide, Methotrexate, and 5-Flourouracil) 
chemotherapy. Conversely, postmenopausal patients 
with moderate or poor NPI and ER-α+ were offered HT, 
while ER-α- patients received CMF if fit. Survival data 
including survival time, disease-free interval (DFI) and 
development of loco-regional and distant metastases (DM) 
were maintained on a prospective basis. Median follow up 
was 124 months (range 1 to 233). Breast cancer specific 
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survival (BCSS) was defined as the time (in months) from 
the date of the primary surgical treatment to the time of 
death from breast cancer. DFI was defined as the interval 
(in months) from the date of the primary surgical treatment 
to the first loco-regional or distant metastasis.
This study was approved by the Nottingham 
Research Ethics Committee 2 under the title “Development 
of a molecular genetics classification of breast cancer”. 
Patients consented to tissue samples being used for 
research purposes.
Immunostaining of human breast cancer tissue arrays
The localization and number of kappa and lambda 
FLC protein expressing cells was assessed in formalin 
fixed paraffin embedded (FFPE) tissue microarrays of 
breast cancer to characterize their association with cancer-
relevant biological markers and with clinicopathologic 
features. The cut-offs used for categorizing the various 
biomarkers have been previously described [26]. HER2 
scoring was performed using the Hercept tests guidelines 
(DakoCytomation, Cambridge, UK).
Immunohistochemistry (IHC) was performed using 
a DakoCytomation Techmate 500 plus (DakoCytomation, 
Cambridge, UK) instrument with a linked streptavidin 
biotin technique and DAB chromogen as previously 
described [27]. Primary antibodies were optimized on 
full face FFPE sections and TMAs of breast cancer tissue. 
Negative controls comprised omission of the primary 
antibody and substitution with an inappropriate primary 
antibody of the same Ig class. After dewaxing, sections 
were subjected to microwave antigen retrieval using 
0.01M citrate buffer, pH6 and then immunostained using 
the optimized 1:50 dilution of mouse monoclonal kappa 
(Fκ-C8) and separately, lambda FLC (Fλ-G9) Ab [24].
Staining intensity was subjectively assessed (DGP & 
HOH) for each marker according to a three point scoring 
system comprising: 0 (negative); 1 (weak); or 2 (strong) 
staining intensity confined to the malignant tissue or 
stromal inflammatory cells. Cases were scored without 
knowledge of patient outcome.
Univariate and Multivariate Statistics
The results have been reported according to 
REMARK criteria that establish a framework for reporting 
tumor marker prognostic studies [28]. The association 
between FLC and other tumor-relevant markers was 
assessed using Chi square test. Association with clinical 
outcome including BCSS, DFI, DM formation, and local 
tumor recurrence was modeled using Kaplan-Meier 
plots (Version 15, SPSS Inc, IL, USA) with the log rank 
(Mantel-Cox) test. A p-value of less than 0.05 was deemed 
significant with 95% confidence intervals.
Animal studies
Detection of FLCs and mast cells in mouse B16F10 
melanoma tissue
B16F10 melanoma tumors were developed 
subcutaneously in mice, as described previously [29]. 
In brief, 106 B16F10 cells cultured in vitro were injected 
subcutaneously into the flank of C57Bl/6J wild type or 
mast cell-deficient WBB66FI/J-Kitw/KitW-v mice. For 
mast cell detection, tumors were fixed in 10% buffered 
formaldehyde and embedded in paraffin. Deparaffinized 
sections were stained with toluidine blue solution. FLCs 
were detected by western blotting. For these experiments, 
mouse tumors were collected and immediately 
homogenized and lysed with MT Cell lysis reagent 
containing a protease inhibitor cocktail (Sigma-Aldrich, 
the Netherlands). The lysed sample was centrifuged 
for 10 min at 20000 × g to pellet the tissue debris, 
and the protein supernatant was subjected to western 
blotting (iBlot; Invitrogen, Frederick, MD). Horseradish 
peroxidase-labeled goat anti-mouse kappa light chain (0.1 
μg/mL, SouthernBiotech, Birmingham, USA) was used to 
immunostain the membranes.
Treatment with the peptide antagonist F991
C57Bl/6J wild type or mast cell-deficient 
WBB66FI/J-Kitw/KitW-v mice that received B16F10 cells 
via subcutaneous flank injection were monitored for 
tumor growth. At the time the tumor became palpable, 
25 µl PBS containing 20 µg F991 or vehicle alone was 
injected in the tumor vicinity. Treatment was repeated 
weekly. Tumor growth was monitored by measuring the 
largest and smallest superficial diameters of the tumors 
using digital calipers. The tumor volume was calculated as 
follows: (0.52 x largest diameter) x (smallest diameter2). 
Animals were considered to have reached the endpoint of 
the experiment when the tumor volume measured ≥ 1500 
mm3.
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